AZD9496 is an investigational selective estrogen receptor degrader (SERD) designed for the treatment of estrogen receptor-positive (ER+) breast cancer. It functions by binding to the estrogen receptor and promoting its degradation, thereby inhibiting estrogen-driven tumor growth. This compound is particularly developed for use in advanced or metastatic ER+ breast cancer, especially in cases resistant to other endocrine therapies. AZD9496 has been studied in preclinical and clinical settings to evaluate its efficacy as an oral therapy, offering a potential alternative to injectable SERDs. Its development aims to improve treatment options for patients who have progressed on standard hormonal therapies such as aromatase inhibitors or selective estrogen receptor modulators (SERMs).